7OFC
Keap1 kelch domain bound to a small molecule fragment
Summary for 7OFC
| Entry DOI | 10.2210/pdb7ofc/pdb |
| Descriptor | Kelch-like ECH-associated protein 1, DIMETHYL SULFOXIDE, ~{N},~{N}-dimethyl-9-oxidanylidene-fluorene-4-carboxamide, ... (5 entities in total) |
| Functional Keywords | keap1, nrf2, oxidative stress, small molecule complex, maybridge, peptide binding protein |
| Biological source | Mus musculus (Mouse) |
| Total number of polymer chains | 1 |
| Total formula weight | 34022.17 |
| Authors | Narayanan, D.,Bach, A.,Gajhede, M. (deposition date: 2021-05-04, release date: 2022-11-02, Last modification date: 2024-01-31) |
| Primary citation | Narayanan, D.,Tran, K.T.,Pallesen, J.S.,Solbak, S.M.O.,Qin, Y.,Mukminova, E.,Luchini, M.,Vasilyeva, K.O.,Gonzalez Chichon, D.,Goutsiou, G.,Poulsen, C.,Haapanen, N.,Popowicz, G.M.,Sattler, M.,Olagnier, D.,Gajhede, M.,Bach, A. Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery. J.Med.Chem., 65:14481-14526, 2022 Cited by PubMed Abstract: Targeting the protein-protein interaction (PPI) between the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and its repressor, Kelch-like ECH-associated protein 1 (Keap1), constitutes a promising strategy for treating diseases involving oxidative stress and inflammation. Here, a fragment-based drug discovery (FBDD) campaign resulted in novel, high-affinity ( = 280 nM), and cell-active noncovalent small-molecule Keap1-Nrf2 PPI inhibitors. We screened 2500 fragments using orthogonal assays─fluorescence polarization (FP), thermal shift assay (TSA), and surface plasmon resonance (SPR)─and validated the hits by saturation transfer difference (STD) NMR, leading to 28 high-priority hits. Thirteen co-structures showed fragments binding mainly in the P4 and P5 subpockets of Keap1's Kelch domain, and three fluorenone-based fragments featuring a novel binding mode were optimized by structure-based drug discovery. We thereby disclose several fragment hits, including their binding modes, and show how FBDD can be performed to find new small-molecule Keap1-Nrf2 PPI inhibitors. PubMed: 36263945DOI: 10.1021/acs.jmedchem.2c00830 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.97 Å) |
Structure validation
Download full validation report
